Yahoo Finance 
J&J, AbbVie, and Amgen Among Dominant Players in the Plaque Psoriasis Drugs Market | GlobalData Plc
Sales of Remicade, Stelara, and Tremfya cemented J&J as one of the major companies occupying the PsO market
LONDON, July 20, 2022 (GLOBE NEWSWIRE) -- The “Plaque Psoriasis (PsO): Global Drug Forecast and Market Analysis to 2030” report offered by GlobalData provides an overview of plaque psoriasis including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. Additionally, the report analyses topline plaque psoriasis market revenue, the annual cost of therapy, and major pipeline product sales in the forecast period.
The sales of plaque psoriasis therapeutics totaled $14.2 billion in 2020 in the 7MM. The market is anticipated to experience growth at a CAGR of more than 6% by 2030. The global market growth is driven by the steady increase in total diagnosed prevalence across the 7MM.
For more detailed statistics on plaque psoriasis market sizing and forecast, download a sample report
Plaque Psoriasis Drugs Market Drivers
The steady increase in total diagnosed prevalence across the 7MM and the launches of eight new pipeline products: Bimzelx (bimekizumab), sonelokimab, ABY-035/izokibep, roflumilast, tapinarof, deucravacitinib, tepilamide fumarate, and piclidenoson will fuel the plaque psoriasis drugs market growth during the forecast period. The increased treatment options for mild and moderate patients, a historically undertreated population will also support the growth of the market.
For more insights on the plaque psoriasis market drivers and challenges, download a sample report
Plaque Psoriasis Market - Unmet Needs and Opportunities Assessment
Despite the number of therapies already available for PsO, several key commercial and clinical unmet needs remain. Unmet clinical needs in PsO include the need for novel topical therapeutics as well as new therapies that target the subgroups of the mildest and the most severe patients. Patient access continues to be a significant commercial unmet need as the high cost of biologic therapies can present a significant barrier to care. However, the advent of novel pipeline therapeutics and the launch of both biosimilars and generics opens the door for more PsO patients to access care.
For more insights on unmet needs and opportunities in the plaque psoriasis market, download a sample report
Plaque Psoriasis Market - Pipeline Assessment
Given the dominance of biologics in the last decade, the current PsO pipeline is surprisingly innovative, both in terms of new mechanisms of action as well as new companies entering the development space. More recently, there has also been an increased focus on the small molecule oral and topical therapeutics market. Over the 10-year forecast period, it has been forecast that eight products in late-stage development will launch in the 7MM. Growth within the markets will be largely driven by the launch and uptake of three IL-17 inhibitors, UCB’s bimekizumab, Merck’s sonelokimab, and Affibody’s ABY-035; three small oral therapeutics, Bristol-Myers Squibb’s deucravacitinib, Dr. Reddy’s tepilamide fumarate, and Can-Fite Biopharma’s piclidenoson; and two topical therapies, Arcutis’ roflumilast and Dermavant’s tapinarof.
For more insights on plaque psoriasis drugs pipeline and forecast, download a sample report
Plaque Psoriasis Market - Competitive Landscape
Most first-line therapies for mild PsO patients are highly genericized. This includes topical orticosteroids and vitamin A and vitamin D derivatives. Conversely, there is heavy competition within the PsO market, focusing on biologic drugs targeting patients with moderate to severe disease. Currently, the only oral therapy that is currently marketed for psoriasis is Amgen’s small molecule PDE4 inhibitor, Otezla. Since its approval, Otezla has proven to be a safe drug and has been used by physicians across the 7MM. However, KOLs have noted that their efficacy is not as strong as available biologic therapies and thus physicians are less inclined to use it.
Historically, J&J, AbbVie, and Amgen have been dominant companies in the PsO market. Sales of Remicade, Stelara, and Tremfya cemented J&J as one of the major companies occupying the PsO market. Despite J&J having no pipeline products, Tremfya should remain patent-protected throughout the forecast period. AbbVie also has a commanding presence in the field due to marketing both Humira and Skyrizi.
Leading Companies in the Plaque Psoriasis Market
J&J
Amgen
AbbVie
Novartis
Bristol Myers Squibb
Eli Lilly
SunPharma
Merck
Affibody
Dr. Reddy’s Laboratories
To know more about leading companies in the plaque psoriasis market, download a sample report
Plaque Psoriasis Market Report Scope
Overview of PsO including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Topline PsO market revenue, the annual cost of therapy, and major pipeline product sales in the forecast period.
Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting PsO therapeutics sales in the 7MM.
Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future market competition in the global PsO therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
Develop business strategies by understanding the trends shaping and driving the global PsO therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PsO market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global PsO therapeutics market from 2020-2030.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Related Reports
Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update – Click here
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update – Click here
Sjogrens Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape – Click here
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type, and Key Players, 2022 Update – Click here
Waldenstrom Macroglobulinemia (WM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape – Click here
Plaque Psoriasis Market Overview
Market Size 2020 | $14.2 billion |
CAGR (2020-2030) | >6% |
Leading Companies | J&J, Amgen, AbbVie, Novartis, Bristol Myers Squibb, Eli Lilly, SunPharma, Merck, Affibody, Dr. Reddy’s Laboratories, and Others |
FAQs
What was the plaque psoriasis market size in 2020?
The plaque psoriasis market size was valued at $14.2 billion in 2020.
What is the plaque psoriasis market growth rate?
The plaque psoriasis market is expected to grow at a CAGR of more than 6% during the forecast period.
Which are the leading companies in the plaque psoriasis market?
The leading companies in the plaque psoriasis market are J&J, Amgen, AbbVie, Novartis, Bristol Myers Squibb, Eli Lilly, SunPharma, Merck, Affibody, and Dr. Reddy’s Laboratories.
Table of Contents
1 Plaque Psoriasis: Executive Summary
1.1 PsO Market to Experience Conservative Growth from 2020–2030
1.2 New Players to Enter a Saturated Field
1.3 Opportunities Remain for Undertreated Patient Populations
1.4 Innovator Small Molecules Dominate the Late-Stage Pipeline
1.5 What Do Physicians Think?
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 Forecast Methodology
4.4.1 Sources Used
4.4.2 Forecast Assumptions and Methods
4.5 Epidemiological Forecast for PsO (2020–2030)
4.5.1 Lifetime Diagnosed Prevalent Cases of PsO
4.5.2 Age–Specific Lifetime Diagnosed Prevalent Cases of PsO
4.5.3 Sex-Specific Lifetime Diagnosed Prevalent Cases of PsO
4.5.4 Lifetime Diagnosed Prevalent Cases of PsO by Severity in the Adult Population
4.5.5 Lifetime Diagnosed Prevalent Cases of PsO with PsA in the Adult Population
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of Analysis
4.6.4 Strengths of Analysis
5 Disease Management
5.1 Diagnosis
5.2 Treatment
5.2.1 Impact of COVID-19
6 Competitive Assessment
6.1 Overview
6.1.1 TNF Inhibitors
6.1.2 IL-17 Inhibitors
6.1.3 IL-23 Inhibitors
6.1.4 Other Disease Modifying Therapies
6.2 Biosimilars
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Cost-Effective Therapies
7.3 Efficacious Therapies for Treatment Refractory Patients
7.4 Lack of Innovative Topical Therapies
7.5 Treatment Options for Mild PsO Patients
8 R&D Strategies
8.1 Overview
8.1.1 Development Shift Away from Injectable Biologics
8.1.2 New Players Enter the Late-Stage Pipeline
8.2 Clinical Trials Design
8.2.1 Robust Clinical Endpoints
8.2.2 Long-Term Patient Follow-Up
8.2.3 Active Comparator Trials
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.2.1 Bimzelx (bimekizumab)
9.2.2 Sonelokimab/M1095
9.2.3 ABY-035/izokibep
9.2.4 Tapinarof/DMVT-505
9.2.5 Roflumilast
9.2.6 Deucravacitinib
9.2.7 Piclidenoson
9.2.8 Tepilamide fumarate
9.3 Other Drugs of Note
9.3.1 Mirikizumab
9.3.2 Brepocitinib tosylate
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive Assessment
10.2.1 Biologic Medications
10.2.2 Small Molecule Therapeutics
11 Current and Future Players
11.1 Overview
11.2 Deal-Making Trends
12 Market Outlook
12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and Barriers – Global Issues
12.2 US
12.2.1 Forecast
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key Events
12.3.3 Drivers and Barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key Events
12.4.3 Drivers and Barriers
13 Appendix
13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting Methodology
13.4 Primary Research – KOLs and Payors Interviewed for This Report
13.4.1 KOLs
13.4.2 Payors
13.5 Primary Research – Prescriber Survey
13.6 About the Authors
13.6.1 Analyst
13.6.2 Managing Analyst
13.6.3 Therapy Area Director
13.6.4 Epidemiologist
13.6.5 Reviewers
13.6.6 Global Head and EVP of Healthcare Operations and Strategy
About GlobalData
GlobalData is a leading provider of data, analytics, and insights on the world's largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision makers to predict and navigate the future. This is why GlobalData's mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on GlobalData for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.
Media Contacts
GlobalData
Mark Jephcott
Head of PR EMEA
mark.jephcott@globaldata.com
cc: pr@globaldata.com
+44 (0)207 936 6400
